Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -56.71% is in line with its 5-year average of -57.86%, around the middle of its 5-year range (-88.27%–-19.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.73% above its 12-month average of -61.46%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -56.71%.
RETURN ON EQUITY (ROE)
-56.71%
RETURN ON EQUITY (ROE) AVG TTM
-61.46%
RETURN ON EQUITY (ROE) AVG 3Y
-63.93%
RETURN ON EQUITY (ROE) AVG 5Y
-57.86%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.73%
CURRENT VS 3Y AVG
+11.29%
CURRENT VS 5Y AVG
+1.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
11.44%
median of 92 covered companies
CURRENT VS SECTOR MEDIAN
-595.71%
vs the sector median at left
Recursion Pharmaceuticals, Inc.
Market Cap
$2.14B
Return on Equity (ROE)
-56.71%
TTM Avg
-61.46%
3Y Avg
-63.93%
5Y Avg
-57.86%
Market Cap
$2.51B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$1.73B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.72B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$2.74B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$1.00B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$472.39M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$459.30M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$397.55M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | -56.71% | -61.46% | -63.93% | -57.86% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | -8.00% | -28.91% | -27.68% | -39.13% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | -40.41% | -45.75% | -30.11% | -18.95% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | -54.96% | -60.50% | -51.30% | -42.73% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 29.28% | 27.86% | 4.54% | -12.45% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -13.54% | -40.81% | -170.75% | -114.78% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | -6.60% | -10.82% | -11.36% | -7.59% |
| NRC Health (NRC)vs › | $459.30M | 89.43% | 81.07% | 67.39% | 61.90% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | -28.18% | -0.06% | 10.58% | 10.58% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | -285.38% | -206.98% | -151.57% |
ROE
-56.7%
ROA
-42.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -56.71% |
| 2026-03-31 | -54.62% |
| 2025-12-31 | -57.01% |
| 2025-09-30 | -68.35% |
| 2025-06-30 | -70.61% |
| 2025-03-31 | -61.52% |
| 2024-12-31 | -44.79% |
| 2024-09-30 | -71.98% |
| 2024-06-30 | -64.15% |
| 2024-03-31 | -88.27% |
| 2023-12-31 | -70.79% |
| 2023-09-30 | -66.80% |
| 2023-06-30 | -55.44% |
| 2023-03-31 | -57.84% |
| 2022-12-31 | -49.29% |
| 2022-09-30 | -63.63% |
| 2022-06-30 | -53.45% |
| 2022-03-31 | -42.90% |
| 2021-12-31 | -34.35% |
| 2021-09-30 | -24.59% |
| 2021-06-30 | -19.26% |
